- English
- En Español
ECCO-ESMO: Antibody-Chemo Combo Promising in Breast Cancer
From MedPageToday.com - Originally published September 25, 2011
STOCKHOLM -- A novel monoclonal antibody-guided therapy for HER2-positive metastatic breast cancer extended disease-free survival compared with standard treatment, researchers said here.
In a phase II trial, patients on the investigational treatment called trastuzumab emtansine, or T-DM1, achieved roughly a 40% reduction in risk of disease progression compared with those on a standard combination of trastuzumab (Herceptin) plus docetaxel (Taxotere) (P=0.035), according to Sara Hurvitz, MD, director of breast oncology at the University of California Los Angeles.
Hurvitz reported the findings during a press briefing here at the European Multidisciplinary Cancer Congress, formerly known as the joint congress of the European Cancer Organization and European Society for Medical Oncology (ECCO-ESMO).
OBTENGA APOYO
Llámenos al 1-800-221-2141. Sobrevivientes de cáncer de mama están disponibles 24 horas al día, 7 días a la semana.
¿Tiene alguna pregunta? Mándenos un correo electrónico. Su respuesta será contestada dentro 24 horas. Las respuestas son confidenciales.
Participe en el foro de cáncer de mama. Hable con una consejera que ha tenido un diagnostico similar.
Aprenda más acerca del Programa de Coincidencia de Sobrevivientes.
NOTICIAS SOBRE CÁNCER DE MAMA
Radiation therapy following breast conserving surgery reduced the rate of disease recurrence by half, a large meta-analysis found.
Regular surveillance mammography after breast cancer boosts survival and should be continued for at least a decade, a systematic review suggested.
STOCKHOLM -- A novel monoclonal antibody-guided therapy for HER2-positive metastatic breast cancer extended disease-free survival compared with...